Carillon Tower Advisers, an investment management company, released its second-quarter 2026 investor letter for the “Carillon Eagle Mid Cap Growth Fund”. A copy of the letter is available to download here. Mid-cap stocks delivered strong results, with the Russell Midcap® Growth Index rising 14.55% and slightly outperforming the Russell Midcap® Value Index’s 13.40% gain. Information technology led the growth index with a 36.90% return, while industrials also outperformed, and energy was the only sector to decline. The quarter was supported by resilient corporate earnings, economic growth and AI infrastructure spending, although geopolitical tensions, higher energy prices and election-related uncertainty could create volatility. The firm remains optimistic that data-center investment will support technology, energy, defense and automation companies, while attractive healthcare valuations and stronger merger activity could create opportunities. However, financials and consumer stocks face mixed conditions because of housing weakness, inflation and uneven spending. In addition, please check the Fund’s top five holdings to know its best picks in 2026.
In its second-quarter 2026 investor letter, Carillon Eagle Mid Cap Growth Fund highlighted Cencora (NYSE:COR). Cencora (NYSE:COR) is a global pharmaceutical sourcing and distribution services company serving healthcare providers and manufacturers. On July 30, 2026, Cencora, Inc. (NYSE:COR) closed at $311.15 per share. The one-month return of Cencora, Inc. (NYSE:COR) was 4.74%, and its shares gained 7.70% over the past 52 weeks. Cencora, Inc. (NYSE:COR) has a market capitalization of $60.75 billion.
Carillon Eagle Mid Cap Growth Fund stated the following regarding Cencora, Inc. (NYSE:COR) in its Q2 2026 investor letter:
“Cencora, Inc. (NYSE:COR) is a pharmaceutical distributor and healthcare services company that supports drug manufacturers, pharmacies, providers, and health systems. The company beat first-quarter revenue estimates but underperformed as it lowered full-year revenue guidance. The guidance reduction reflected slower than expected growth of GLP-1 drugs, drug list price reductions, softer sales to a large mail-order customer, and the loss of a large oncology customer to a competitor. Despite these temporary setbacks, we continue to believe that steady growth from new drugs and drugs going off patent make drug distribution one of the most durable businesses in healthcare. We expect generic conversions to provide a tailwind over time because generic drugs carry higher profit margins than branded drugs.”
Cencora, Inc. (NYSE:COR) is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 61 hedge fund portfolios held Cencora, Inc. (NYSE:COR) at the end of the first quarter which was 61 in the previous quarter. While we acknowledge the risk and potential of Cencora, Inc. (NYSE:COR) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than Cencora, Inc. (NYSE:COR) and that has 10,000% upside potential, check out our report about this cheapest AI stock.
In another article, we covered Cencora, Inc. (NYSE:COR) and shared Latitude Investment Management’s views on the company. In addition, please check out our hedge fund investor letters Q2 2026 page for more investor letters from hedge funds and other leading investors.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. This article is originally published at Insider Monkey.
